AIDX 8-K SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

AIDX ▼ -21.49% at T+5d

SHORT call ✓ call won +21.49% · α vs SPY +23.09% · entry $1.21 → $0.9500

Next anchor: T+20d in 5d

Currently $0.9600 · +20.66% from $1.21 entry (call sign-flipped)

Entry anchored
May 20, 01:31 PM ET
via Databento tick

T+1d

-19.01%

call +19.01% · α +19.45%

$0.9800

settled 23d ago

T+5d

-21.49%

call +21.49% · α +23.09%

$0.9500

settled 16d ago

T+20d

—

call — · α —

—

in 5d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

20/20 Biolabs reported Q1 2026 revenue of $0.4M, down 36% YoY and 55% below consensus, with EPS of -$0.28 vs. -$0.10 expected. Net loss widened to $2.2M from $0.8M, reflecting higher SG&A costs and non-cash charges. Management guided for a Q2 revenue rebound driven by state-funded firefighter screening programs, but provided no hard financial outlook.

Key Financial Metrics

Free Cash Flow

-$1.3M

Gross Margin

17.8%

Actionable Insight

Watch for Q2 2026 revenue confirmation from Maryland and second state firefighter programs; current cash runway likely insufficient beyond 12 months without additional financings. The $5M private placement and up to $40M preferred purchase agreement provide near-term liquidity, but dilution risk persists.

Key Facts

Revenue $353,375 in Q1 2026, down from $553,820 in Q1 2025
Basic EPS -$0.28 vs consensus estimate -$0.10
Net loss $2,174,836 vs $764,577 in prior year
Gross margin compressed to 17.8% from 29.9%
Cash and equivalents $4.2M at March 31, 2026, up from $1.0M at Dec 31, 2025
Deferred revenue increased to ~$0.5M, providing revenue visibility
Second state firefighter cancer screening program expected to contribute in future periods

Financial Impact

Revenue miss of 55% vs consensus; net loss more than doubled YoY

revenueepsnet incomegross margin

Risk Factors

Revenue concentration on government firefighter screening programs
Cash burn rate implies need for additional capital within 12 months
Gross margin decline due to lower absorption of fixed costs
Potential dilution from Series E preferred stock conversion and additional tranches

Market Snapshot

Exchange

Nasdaq

Sector

Services-Testing Laboratories

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001213900-26-059526
Document: ea0291642-8k_2020bio.htm	0001213900-26-059526
Document: 0001213900-26-059526-index-headers.html	0001213900-26-059526
Document: 0001213900-26-059526-index.html	0001213900-26-059526
Document: 0001213900-26-059526.txt	0001213900-26-059526
8-K Data (Synthetic)	0001213900-26-059526

7 reports for AIDX

T+1T+5T+20T+60

100% Hit rate 3 of 3 directional calls best @ T+20▲ +37.42%Apr 28, 2026

Filters

Reports for AIDX — sortable, filterable
	Type				Now
May 26, 2026 17d ago	8-K NEUTRAL ★ 2/10	$0.9700 $0.8400	▼ −13.40%	▼ −13.87%	$0.9600 (−1.03%)
May 20, 2026 23d ago	8-K BEARISH ★ 6/10	$1.21 $0.9500	▲ +21.49%	▲ +23.09%	$0.9600 (+20.66%)
May 20, 2026 23d ago	Press Release BEARISH ★ 6/10	$1.21 $0.9500	▲ +21.49%	▲ +23.09%	$0.9600 (+20.66%)
Apr 28, 2026 6w ago	8-K BEARISH ★ 6/10	$1.55 $1.49	▲ +3.87%	▲ +5.56%	$0.9600 (+38.06%)
Apr 13, 2026 8w ago	EFFECT NEUTRAL ★ 6/10	$1.85 $1.71	▼ −7.57%	▼ −10.86%	$0.9600 (−48.11%)
Mar 27, 2026 11w ago	Press Release BULLISH ★ 7/10	$1.80 $2.02	▲ +12.22%	▲ +8.36%	$0.9600 (−46.67%)
Mar 24, 2026 11w ago	Press Release MIXED ★ 5/10	$1.64 $1.88	▲ +14.63%	▲ +15.06%	$0.9600 (−41.46%)

US Market Status

Market Closed — Opens Mon (48h 14m)

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access